Novo Nordisk’s semaglutide has proven its cardioprotective effect in its incarnations as Ozempic and Wegovy, so it is perhaps not too surprising to see it hit in its other form, Rybelsus. Data from the SOUL cardiovascular outcomes study showed that the oral diabetes medicine cut the rate of major adverse CV events by 14% over placebo.
Key Takeaways
- Topline data from the SOUL cardiovascular outcomes study showed that Novo Nordisk’s Rybelsus cut the rate of major adverse CV events by 14% over placebo.
This almost certainly means that a cardioprotective claim will be granted for Rybelsus’s label, but the commercial significance for the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?